Literature DB >> 24196827

The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: an interrupted time series study of 228,876 pregnancies.

William V Bobo1, Richard A Epstein, Rachel M Hayes, Richard C Shelton, Tina V Hartert, Ed Mitchel, Jeff Horner, Pingsheng Wu.   

Abstract

The purpose of this study was to assess whether antidepressant prescribing during pregnancy decreased following release of U.S. and Canadian public health advisory warnings about the risk of perinatal complications with antidepressants. We analyzed data from 228,876 singleton pregnancies among women (aged 15-44 years) continuously enrolled in Tennessee Medicaid with full pharmacy benefits (1995-2007). Antidepressant prescribing was determined through outpatient pharmacy dispensing files. Information on sociodemographic and clinical factors was obtained from enrollment files and linked birth certificates. An interrupted time series design with segmented regression analysis was used to quantify the impact of the advisory warnings (2002-2005). Antidepressant prescribing rates increased steadily from 1995 to 2001, followed by sharper increases from 2002 to late 2004. Overall antidepressant prescribing prevalence was 34.51 prescriptions [95 % confidence interval (CI) 33.37-35.65] per 1,000 women in January 2002, and increased at a rate of 0.46 (95 % CI 0.41-0.52) prescriptions per 1,000 women per month until the end of the pre-warning period (May 2004). During the post-warning period (October 2004-June 2005), antidepressant prescribing decreased by 1.48 (95 % CI 1.62-1.35) prescriptions per 1,000 women per month. These trends were observed for both selective serotonin reuptake inhibitors (SSRI) and non-SSRI antidepressants, although SSRI prescribing decreased at a greater rate. We conclude that antidepressant prescribing to pregnant women in Tennessee Medicaid increased from 1995 to late 2004. U.S. and Canadian public health advisories about antidepressant-associated perinatal complications were associated with steady decreases in antidepressant prescribing from late 2004 until the end of the study period, suggesting that the advisory warnings were impactful on antidepressant prescribing in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24196827      PMCID: PMC3936602          DOI: 10.1007/s00737-013-0383-6

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  50 in total

Review 1.  Clinical practice guidelines. Management of anxiety disorders.

Authors: 
Journal:  Can J Psychiatry       Date:  2006-07       Impact factor: 4.356

2.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.

Authors:  Carol Louik; Angela E Lin; Martha M Werler; Sonia Hernández-Díaz; Allen A Mitchell
Journal:  N Engl J Med       Date:  2007-06-28       Impact factor: 91.245

3.  No easy answers for physicians caring for pregnant women with depression.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2009-12-09       Impact factor: 56.272

4.  Prevalence and patterns of antidepressant drug use during pregnancy.

Authors:  Tessa Ververs; Hans Kaasenbrood; Gerard Visser; Fred Schobben; Lolkje de Jong-van den Berg; Toine Egberts
Journal:  Eur J Clin Pharmacol       Date:  2006-08-08       Impact factor: 2.953

5.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Authors:  Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

Review 6.  The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.

Authors: 
Journal:  Obstet Gynecol       Date:  2009-09       Impact factor: 7.661

7.  National patterns in antidepressant medication treatment.

Authors:  Mark Olfson; Steven C Marcus
Journal:  Arch Gen Psychiatry       Date:  2009-08

8.  Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

Authors:  Raymond W Lam; Sidney H Kennedy; Sophie Grigoriadis; Roger S McIntyre; Roumen Milev; Rajamannar Ramasubbu; Sagar V Parikh; Scott B Patten; Arun V Ravindran
Journal:  J Affect Disord       Date:  2009-08-11       Impact factor: 4.839

Review 9.  Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews.

Authors:  Kurt Kroenke; Erin E Krebs; Matthew J Bair
Journal:  Gen Hosp Psychiatry       Date:  2009-03-04       Impact factor: 3.238

10.  Recall accuracy for prescription medications: self-report compared with database information.

Authors:  S L West; D A Savitz; G Koch; B L Strom; H A Guess; A Hartzema
Journal:  Am J Epidemiol       Date:  1995-11-15       Impact factor: 4.897

View more
  6 in total

Review 1.  Unintended Effects of Communicating About Drug Safety Issues: A Critical Review of the Literature.

Authors:  Jessica T DeFrank; Lauren McCormack; Suzanne L West; Craig Lefebvre; Olivia Burrus
Journal:  Drug Saf       Date:  2019-10       Impact factor: 5.606

Review 2.  Interpreting the pharmacoepidemiology literature in obstetrical studies: A guide for clinicians.

Authors:  Laura J Rasmussen-Torvik; Katelyn B Zumpf; Hannah K Betcher; Jody D Ciolino
Journal:  Semin Perinatol       Date:  2020-02-28       Impact factor: 3.300

Review 3.  Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges.

Authors:  Richard A Epstein; Katherine M Moore; William V Bobo
Journal:  Drug Healthc Patient Saf       Date:  2014-09-18

4.  Maternal depression and antidepressant use during pregnancy and the risk of autism spectrum disorder in offspring.

Authors:  Katrina Wilcox Hagberg; Annelies L Robijn; Susan Jick
Journal:  Clin Epidemiol       Date:  2018-11-01       Impact factor: 4.790

Review 5.  Competent psychopharmacology.

Authors:  David M Gardner
Journal:  Can J Psychiatry       Date:  2014-08       Impact factor: 4.356

Review 6.  The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?

Authors:  Aizati N A Daud; Jorieke E H Bergman; Wilhelmina S Kerstjens-Frederikse; Henk Groen; Bob Wilffert
Journal:  Int J Mol Sci       Date:  2016-08-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.